annual CFO:
$479.06M+$90.49M(+23.29%)Summary
- As of today (June 22, 2025), HALO annual cash flow from operations is $479.06 million, with the most recent change of +$90.49 million (+23.29%) on December 31, 2024.
- During the last 3 years, HALO annual CFO has risen by +$179.62 million (+59.99%).
- HALO annual CFO is now at all-time high.
Performance
HALO Cash from operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly CFO:
$154.22M-$24.25M(-13.59%)Summary
- As of today (June 22, 2025), HALO quarterly cash flow from operations is $154.22 million, with the most recent change of -$24.25 million (-13.59%) on March 31, 2025.
- Over the past year, HALO quarterly CFO has increased by +$24.79 million (+19.16%).
- HALO quarterly CFO is now -13.59% below its all-time high of $178.47 million, reached on December 31, 2024.
Performance
HALO quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM CFO:
$503.86M+$24.79M(+5.18%)Summary
- As of today (June 22, 2025), HALO TTM cash flow from operations is $503.86 million, with the most recent change of +$24.79 million (+5.18%) on March 31, 2025.
- Over the past year, HALO TTM CFO has increased by +$72.82 million (+16.90%).
- HALO TTM CFO is now at all-time high.
Performance
HALO TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash from operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
HALO Cash from operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +23.3% | +19.2% | +16.9% |
| 3 y3 years | +60.0% | +222.7% | +74.4% |
| 5 y5 years | +660.8% | +3283.8% | +687.0% |
HALO Cash from operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +99.5% | -13.6% | +283.4% | at high | +109.8% |
| 5 y | 5-year | at high | +660.8% | -13.6% | +3283.8% | at high | +687.0% |
| alltime | all time | at high | +660.8% | -13.6% | +621.2% | at high | +687.0% |
HALO Cash from operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2025 | - | $154.22M(-13.6%) | $503.86M(+5.2%) |
| Dec 2024 | $479.06M(+23.3%) | $178.47M(+54.7%) | $479.06M(+18.9%) |
| Sep 2024 | - | $115.38M(+106.8%) | $402.95M(-4.1%) |
| Jun 2024 | - | $55.79M(-56.9%) | $419.99M(-2.6%) |
| Mar 2024 | - | $129.43M(+26.5%) | $431.03M(+10.9%) |
| Dec 2023 | $388.57M(+61.8%) | $102.35M(-22.7%) | $388.57M(+5.4%) |
| Sep 2023 | - | $132.41M(+98.1%) | $368.67M(+20.5%) |
| Jun 2023 | - | $66.84M(-23.1%) | $305.89M(+9.5%) |
| Mar 2023 | - | $86.96M(+5.5%) | $279.28M(+16.3%) |
| Dec 2022 | $240.11M(-19.8%) | $82.45M(+18.4%) | $240.11M(-0.0%) |
| Sep 2022 | - | $69.64M(+73.1%) | $240.17M(-17.8%) |
| Jun 2022 | - | $40.23M(-15.8%) | $292.28M(+1.2%) |
| Mar 2022 | - | $47.80M(-42.1%) | $288.94M(-3.5%) |
| Dec 2021 | $299.44M(+440.0%) | $82.52M(-32.2%) | $299.44M(+11.8%) |
| Sep 2021 | - | $121.74M(+230.0%) | $267.84M(+76.0%) |
| Jun 2021 | - | $36.89M(-36.7%) | $152.19M(+28.3%) |
| Mar 2021 | - | $58.30M(+14.5%) | $118.59M(+113.9%) |
| Dec 2020 | $55.45M(-164.9%) | $50.92M(+736.9%) | $55.45M(-351.0%) |
| Sep 2020 | - | $6.08M(+84.7%) | -$22.09M(-61.8%) |
| Jun 2020 | - | $3.29M(-168.0%) | -$57.76M(-32.7%) |
| Mar 2020 | - | -$4.84M(-81.8%) | -$85.84M(+0.5%) |
| Dec 2019 | -$85.42M(+72.6%) | -$26.63M(-10.0%) | -$85.42M(+76.7%) |
| Sep 2019 | - | -$29.59M(+19.4%) | -$48.34M(+28.3%) |
| Jun 2019 | - | -$24.79M(+460.3%) | -$37.67M(+18.7%) |
| Mar 2019 | - | -$4.42M(-142.3%) | -$31.75M(-35.9%) |
| Dec 2018 | -$49.50M(-136.9%) | $10.46M(-155.3%) | -$49.50M(-153.1%) |
| Sep 2018 | - | -$18.93M(+0.4%) | $93.29M(-29.6%) |
| Jun 2018 | - | -$18.86M(-15.0%) | $132.47M(-1.4%) |
| Mar 2018 | - | -$22.18M(-114.5%) | $134.34M(+0.2%) |
| Dec 2017 | $134.05M(-366.1%) | $153.25M(+656.4%) | $134.05M(-483.4%) |
| Sep 2017 | - | $20.26M(-219.2%) | -$34.96M(-45.3%) |
| Jun 2017 | - | -$17.00M(-24.3%) | -$63.97M(+6.9%) |
| Mar 2017 | - | -$22.46M(+42.4%) | -$59.82M(+18.7%) |
| Dec 2016 | -$50.38M(+35.9%) | -$15.77M(+80.2%) | -$50.38M(+1.1%) |
| Sep 2016 | - | -$8.75M(-31.9%) | -$49.81M(-14.2%) |
| Jun 2016 | - | -$12.85M(-1.4%) | -$58.05M(+60.1%) |
| Mar 2016 | - | -$13.02M(-14.3%) | -$36.27M(-2.2%) |
| Dec 2015 | -$37.08M(-22.0%) | -$15.20M(-10.5%) | -$37.08M(+62.5%) |
| Sep 2015 | - | -$16.98M(-290.0%) | -$22.82M(+20.0%) |
| Jun 2015 | - | $8.94M(-164.6%) | -$19.02M(-56.5%) |
| Mar 2015 | - | -$13.84M(+1373.8%) | -$43.73M(-8.0%) |
| Dec 2014 | -$47.52M(-3.7%) | -$939.00K(-92.9%) | -$47.52M(-23.1%) |
| Sep 2014 | - | -$13.18M(-16.4%) | -$61.80M(+1.3%) |
| Jun 2014 | - | -$15.77M(-10.6%) | -$61.03M(+8.6%) |
| Mar 2014 | - | -$17.63M(+15.8%) | -$56.22M(+13.9%) |
| Dec 2013 | -$49.34M | -$15.22M(+22.6%) | -$49.34M(-3.2%) |
| Sep 2013 | - | -$12.41M(+13.3%) | -$50.99M(-3.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2013 | - | -$10.96M(+1.9%) | -$52.87M(-5.0%) |
| Mar 2013 | - | -$10.75M(-36.3%) | -$55.67M(-13.4%) |
| Dec 2012 | -$64.28M(+87.4%) | -$16.87M(+18.0%) | -$64.28M(+5.5%) |
| Sep 2012 | - | -$14.30M(+3.9%) | -$60.91M(+1.4%) |
| Jun 2012 | - | -$13.76M(-28.9%) | -$60.06M(+41.1%) |
| Mar 2012 | - | -$19.36M(+43.3%) | -$42.57M(+24.1%) |
| Dec 2011 | -$34.30M(-24.4%) | -$13.50M(+0.4%) | -$34.30M(+21.8%) |
| Sep 2011 | - | -$13.44M(-459.6%) | -$28.17M(+6.9%) |
| Jun 2011 | - | $3.74M(-133.7%) | -$26.34M(-40.0%) |
| Mar 2011 | - | -$11.09M(+50.4%) | -$43.88M(-3.3%) |
| Dec 2010 | -$45.39M(+13.0%) | -$7.38M(-36.5%) | -$45.39M(-7.3%) |
| Sep 2010 | - | -$11.62M(-15.8%) | -$48.98M(-5.5%) |
| Jun 2010 | - | -$13.79M(+9.4%) | -$51.84M(+5.9%) |
| Mar 2010 | - | -$12.60M(+14.9%) | -$48.97M(+22.0%) |
| Dec 2009 | -$40.15M(+13.5%) | -$10.97M(-24.3%) | -$40.15M(+5.0%) |
| Sep 2009 | - | -$14.48M(+32.6%) | -$38.22M(+11.2%) |
| Jun 2009 | - | -$10.92M(+188.9%) | -$34.36M(+2.1%) |
| Mar 2009 | - | -$3.78M(-58.2%) | -$33.64M(-4.9%) |
| Dec 2008 | -$35.37M(>+9900.0%) | -$9.04M(-14.9%) | -$35.37M(+5.6%) |
| Sep 2008 | - | -$10.62M(+4.2%) | -$33.51M(+82.3%) |
| Jun 2008 | - | -$10.20M(+85.1%) | -$18.38M(+55.3%) |
| Mar 2008 | - | -$5.51M(-23.2%) | -$11.84M(+7912.9%) |
| Dec 2007 | -$147.70K(-102.1%) | -$7.17M(-259.4%) | -$147.70K(-100.6%) |
| Sep 2007 | - | $4.50M(-223.2%) | $23.18M(+46.0%) |
| Jun 2007 | - | -$3.65M(-159.1%) | $15.88M(-1.1%) |
| Mar 2007 | - | $6.18M(-61.8%) | $16.06M(+126.8%) |
| Dec 2006 | $7.08M(-154.5%) | $16.16M(-677.4%) | $7.08M(-155.8%) |
| Sep 2006 | - | -$2.80M(-19.5%) | -$12.68M(-4.4%) |
| Jun 2006 | - | -$3.48M(+24.1%) | -$13.26M(+4.1%) |
| Mar 2006 | - | -$2.80M(-22.2%) | -$12.74M(-2.0%) |
| Dec 2005 | -$13.00M(+68.4%) | -$3.60M(+6.6%) | -$13.00M(+6.5%) |
| Sep 2005 | - | -$3.38M(+14.3%) | -$12.20M(+7.4%) |
| Jun 2005 | - | -$2.96M(-3.3%) | -$11.36M(+14.8%) |
| Mar 2005 | - | -$3.06M(+8.9%) | -$9.90M(+28.2%) |
| Dec 2004 | -$7.72M(>+9900.0%) | -$2.81M(+10.8%) | -$7.72M(+92.5%) |
| Sep 2004 | - | -$2.53M(+69.4%) | -$4.01M(+160.1%) |
| Jun 2004 | - | -$1.50M(+70.3%) | -$1.54M(+170.0%) |
| Mar 2004 | - | -$878.90K(-197.5%) | -$570.80K(+1046.2%) |
| Dec 2003 | -$49.70K(-10.9%) | $901.20K(-1443.1%) | -$49.80K(-95.0%) |
| Sep 2003 | - | -$67.10K(-87.2%) | -$990.50K(+6.1%) |
| Jun 2003 | - | -$526.00K(+47.0%) | -$933.90K(+132.9%) |
| Mar 2003 | - | -$357.90K(+806.1%) | -$401.00K(+619.9%) |
| Dec 2002 | -$55.80K(+62.2%) | -$39.50K(+276.2%) | -$55.70K(+243.8%) |
| Sep 2002 | - | -$10.50K(-252.2%) | -$16.20K(+184.2%) |
| Jun 2002 | - | $6900.00(-154.8%) | -$5700.00(-54.8%) |
| Mar 2002 | - | -$12.60K | -$12.60K |
| Dec 2001 | -$34.40K | - | - |
FAQ
- What is Halozyme Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Halozyme Therapeutics?
- What is Halozyme Therapeutics annual CFO year-on-year change?
- What is Halozyme Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Halozyme Therapeutics?
- What is Halozyme Therapeutics quarterly CFO year-on-year change?
- What is Halozyme Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Halozyme Therapeutics?
- What is Halozyme Therapeutics TTM CFO year-on-year change?
What is Halozyme Therapeutics annual cash flow from operations?
The current annual CFO of HALO is $479.06M
What is the all time high annual CFO for Halozyme Therapeutics?
Halozyme Therapeutics all-time high annual cash flow from operations is $479.06M
What is Halozyme Therapeutics annual CFO year-on-year change?
Over the past year, HALO annual cash flow from operations has changed by +$90.49M (+23.29%)
What is Halozyme Therapeutics quarterly cash flow from operations?
The current quarterly CFO of HALO is $154.22M
What is the all time high quarterly CFO for Halozyme Therapeutics?
Halozyme Therapeutics all-time high quarterly cash flow from operations is $178.47M
What is Halozyme Therapeutics quarterly CFO year-on-year change?
Over the past year, HALO quarterly cash flow from operations has changed by +$24.79M (+19.16%)
What is Halozyme Therapeutics TTM cash flow from operations?
The current TTM CFO of HALO is $503.86M
What is the all time high TTM CFO for Halozyme Therapeutics?
Halozyme Therapeutics all-time high TTM cash flow from operations is $503.86M
What is Halozyme Therapeutics TTM CFO year-on-year change?
Over the past year, HALO TTM cash flow from operations has changed by +$72.82M (+16.90%)